Cargando…
Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report
BACKGROUND: As a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib is the standard treatment for patients with EGFR mutations. Diarrhea and rash are the most common side effects, and some rare adverse reactions have started appearing owing to their i...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087996/ https://www.ncbi.nlm.nih.gov/pubmed/37057122 http://dx.doi.org/10.21037/tlcr-22-916 |